Eye tracking could unlock new biomarker for angelman syndrome
NCT ID NCT06737718
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will use eye tracking to measure how children with Angelman syndrome look at social and non-social images. Researchers hope to identify abnormalities in social perception that could serve as a biomarker for future treatment trials. The study includes 40 children with Angelman syndrome and 20 healthy controls, all aged 3 to 17.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, eye tracking could become a reliable biomarker to measure social improvements in future Angelman syndrome clinical trials.
- What could go wrong
- This is an early observational study with only 60 participants, so results may not apply to all children with Angelman syndrome. Eye tracking may not detect meaningful differences.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Children with Angelman syndrome followed at Necker-Enfants Malades hospital, Assistance Publique-Hôpitaux de Paris in the Centre Expert Angelman and healthy volunteer children from the patients' entourage, without known neurological, genetic or psychiatric pathology.
- Ages
-
3 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 40 children with Angelman syndrome diagnosed by genetic assessment or EEG. * 20 healthy volunteer control children with no known genetic or psychiatric neurological pathology. * Aged between 3 - 17 years. * Male or female. * Holders of parental authority and minors informed and not opposed to participation in the research. Exclusion Criteria: * Refusal to participate in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Angelman syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Necker-Enfants Malades
RECRUITINGParis, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a worldwide patient registry unlock better treatments for angelman syndrome?
- Can a spinal injection unlock speech in angelman syndrome?
- Can early parent coaching help infants with rare genetic disorders thrive?
- Newborn screening study aims to catch rare diseases at birth
- New hope for angelman syndrome: drug trial targets brain function
- New registry aims to shed light on angelman syndrome